Effects of microRNA-106b on hepatic gluconeogenesis and its underlying mechanism

doi:10.12047/j.cjap.5984.2020.107

Abstract

Abstract: Objective: To investigate the potential effects of microRNA-106b (miR-106b) on gluconeogenesis in normal human liver cell line L02 and its underlying mechanisms. Methods: Normal human liver L02 cells were cultured in DMEM containing 10% FBS and transfected with 20 nmol/L of miR-106b mimic or antagomiR-106b, respectively. Twenty-four hours later after transfection, Western blot was performed to detect the levels of proteins or phosphorylated proteins. Quantitative RT-PCR was carried out to measure the mRNA expressions of gluconeogenesis-related genes. Glucose Assay Kit was used to detect the glucose contents in the medium. Results: MiR-106b mimic significantly increased the protein abundances of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)(P＜0.01,P＜0.01, respectively), enhanced the mRNA expression of phosphoenolpyruvate carboxykinase 1 (PCK1) (P＜0.01), and decreased the mRNA level of glucokinase (GCK) (P＜0.01). AntagomiR-106b dramatically reduced the protein levels of PEPCK and G6Pase (P＜0.01,P＜0.01, respectively), suppressed the mRNA level of PCK1 (P＜0.01), and increased the mRNA level of GCK(P＜0.01). In addition,miR-106b mimic or antagomiR-106b significantly reduced or enhanced the protein levels of signal transducer and activator of transcription 3 (STAT3)(P＜0.01,P＜0.01, respectively).The inhibition of STAT3 by its specific inhibitor abolished the inhibitory effects of antagomiR-106b on hepatic gluconeogenesis. Conclusion: miR-106b increases hepatic gluconeogenesis by inhibiting the STAT3 signaling pathway.

Key words: MicroRNA-106b, gluconeogenesis, STAT3, hepatocytes

CLC Number:

R363.2

FU Xue-dong, WANG Shou-yi, ZHU Zhi-qiang, DENG You-ping. Effects of microRNA-106b on hepatic gluconeogenesis and its underlying mechanism[J]. CJAP, 2020, 36(5): 503-508.

References

[1] Hatting M, Tavares CDJ, Sharabi K, et al. Insulin regulation of gluconeogenesis[J]. Ann NY AcadSci, 2018, 1411(1): 21-35.
[2] Rines AK, Sharabi K, Tavares CD, et al. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes[J]. Nat Rev Drug Discov, 2016, 15(11): 786-804.
[3] Li K, Zhang J, Yu J, et al. MicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4[J]. J Biol Chem, 2015, 290(13): 8185-8195.
[4] Yan C, Chen J, Li M, et al. A decrease in hepatic microRNA-9 expression impairs gluconeogenesis by targeting FOXO1 in obese mice[J]. Diabetologia, 2016, 59(7):1524-1532.
[5] Zhuo S, Yang M, Zhao Y, et al. MicroRNA-451 Negatively regulates hepatic glucose production and glucose homeostasis by targeting glycerol kinase-mediated gluconeogenesis[J]. Diabetes, 2016, 65(11): 3276-3288.
[6] Luo A, Yan H, Liang J, et al. MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1[J]. Gene, 2017, 627: 194-201.
[7] Cheng Y, Guo Y, Zhang Y, et al. MicroRNA-106b is involved in transforming growth factor β1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma[J]. J Exp Clin Cancer Res, 2016, 35: 11.
[8] Yang TS, Yang XH, Chen X, et al. MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN[J]. FEBS Lett, 2014, 588(13): 2162-2169.
[9] An Z, Yang G, Nie W, et al. MicroRNA-106b overexpression alleviates inflammation injury of cardiac endothelial cells by targeting BLNK via the NF-κB signaling pathway[J]. J Cell Biochem, 2018, 119(4): 3451-3463.
[10]Zhang Y, Yang L, Gao YF, et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2[J]. Mol Cell Endocrinol, 2013, 381(1-2): 230-240.
[11]Chen GQ, Lian WJ, Wang GM, et al. Altered microRNA expression in skeletal muscle results from high-fat diet-induced insulin resistance in mice[J]. Mol Med Rep, 2012, 5(5): 1362-1368.
[12]孙晓娟, 冯武龙, 侯娜. JAK2/STAT3信号通路在运动预适应抗心肌细胞凋亡中的作用[J]. 中国应用生理学杂志, 2017, 33 (5): 393-397.
[13]史迎莉, 刘芳, 张晓芹, 等. 胰腺p-STAT3在急性胰腺炎危重演变中的表达变化[J]. 中国应用生理学杂志, 2016, 32 (5): 450-453.
[14]Inoue H, Ogawa W, Ozaki M, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo[J]. Nat Med, 2004, 10(2): 168-174.
[15]Ramadoss P, Unger-Smith NE, Lam FS, et al. STAT3 targets the regulatory regions of gluconeogenic genes in vivo[J]. Mol Endocrinol, 2009, 23(6): 827-837.
[16]Nie Y, Erion DM, Yuan Z, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1[J]. Nat Cell Biol, 2009, 11(4): 492-500.
[17]Carraro G, El-Hashash A, Guidolin D, et al. miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution[J]. Dev Biol, 2009, 333(2): 238-250.
[18]Maimaiti A, Maimaiti A, Yang Y, et al. MiR-106b exhibits an anti-angiogenic function by inhibiting STAT3 expression in endothelial cells[J]. Lipids Health Dis, 2016, 15: 51.
[19]Li Y, Ren Q, Zhu L, et al. Involvement of methylation of microRNA-122, -125b and -106b in regulation of cyclin G1, CAT-1 and STAT3 target genes in isoniazid-induced liver injury[J]. BMC Pharmacol Toxicol, 2018, 19(1): 11.
[20]Zhou K, Zhang T, Fan Y, et al. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN[J]. TumourBiol, 2016, 37(10): 13469-13477.
[21]Wu K, Chang Q, Lu Y, et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells[J]. Oncotarget, 2013, 4(12): 2430-2438.